Overview of Ferroptosis and Synthetic Lethality Strategies

DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer

(2021) Chao Mao et al.   NATURE

Synthetic Lethality in Cancer Therapeutics: The Next Generation

(2021) Jeremy Setton et al.   Cancer Discovery

Endogenous hydrogen sulfide regulates xCT stability through persulfidation of OTUB1 at cysteine 91 in colon cancer cells

(2021) Shanwen Chen et al.   NEOPLASIA

Ferroptosis: past, present and future

(2020) Jie Li et al.   Cell Death & Disease

Aldehyde dehydrogenase 3a2 protects AML cells from oxidative death and the synthetic lethality of ferroptosis inducers

(2020) Rushdia Yusuf et al.   BLOOD

Lipid peroxidation and ferroptosis: The role of GSH and GPx4

(2020) Fulvio Ursini et al.   FREE RADICAL BIOLOGY AND MEDICINE

Targeting apoptosis in cancer therapy

(2020) Benedito A. Carneiro et al.   Nature Reviews Clinical Oncology

Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer

(2020) Annalisa Lorenzato et al.   Cancers

xCT inhibitor sulfasalazine depletes paclitaxel‑resistant tumor cells through ferroptosis in uterine serous carcinoma

(2020) Akiko Sugiyama et al.   Oncology Letters

Geldanamycin-Derived HSP90 Inhibitors Are Synthetic Lethal with NRF2

(2020) Liam Baird et al.   MOLECULAR AND CELLULAR BIOLOGY

Systematic identification of a nuclear receptor-enriched predictive signature for erastin-induced ferroptosis

(2020) Ok-Seon Kwon et al.   Redox Biology

Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis

(2020) Nandini Verma et al.   Science Advances

Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers

(2019) Hideaki Ogiwara et al.   CANCER CELL

The molecular machinery of regulated cell death

(2019) Daolin Tang et al.   CELL RESEARCH

WRN helicase is a synthetic lethal target in microsatellite unstable cancers

(2019) Edmond M. Chan et al.   NATURE

CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy

(2019) Weimin Wang et al.   NATURE

Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens

(2019) Fiona M. Behan et al.   NATURE

Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer

(2019) Luca Lazzari et al.   CLINICAL CANCER RESEARCH

A Compendium of Genetic Modifiers of Mitochondrial Dysfunction Reveals Intra-organelle Buffering

(2019) Tsz-Leung To et al.   CELL

A powerful cell-protection system prevents cell death by ferroptosis

(2019) Brent R. Stockwell   NATURE

FSP1 is a glutathione-independent ferroptosis suppressor

(2019) Sebastian Doll et al.   NATURE

The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis

(2019) Kirill Bersuker et al.   NATURE

A back-up plan

(2019) Grant Miura   Nature Chemical Biology

Synthetic lethality as an engine for cancer drug target discovery

(2019) Alan Huang et al.   NATURE REVIEWS DRUG DISCOVERY

Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets

(2019) Joshua M. Dempster et al.   Nature Communications

Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma

(2019) Kewen Hu et al.   JOURNAL OF CLINICAL INVESTIGATION

Fumarate hydratase inactivation in hereditary leiomyomatosis and renal cell cancer is synthetic lethal with ferroptosis induction

(2018) Michael J. Kerins et al.   CANCER SCIENCE

Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics

(2018) Li Ding et al.   CELL

Oncogenic Signaling Pathways in The Cancer Genome Atlas

(2018) Francisco Sanchez-Vega et al.   CELL

p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells

(2018) Amy Tarangelo et al.   Cell Reports

Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells

(2018) Shogo Okazaki et al.   Oncotarget

NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer

(2018) Valentina Gambardella et al.   CLINICAL CANCER RESEARCH

Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway

(2017) Vasanthi S. Viswanathan et al.   NATURE

Salinomycin kills cancer stem cells by sequestering iron in lysosomes

(2017) Trang Thi Mai et al.   Nature Chemistry

Synthetic lethality screens point the way to new cancer drug targets

(2017) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Synthetic lethality and cancer

(2017) Nigel J. O'Neil et al.   NATURE REVIEWS GENETICS

PARP inhibitors: Synthetic lethality in the clinic

(2017) Christopher J. Lord et al.   SCIENCE

The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity

(2017) Yangchun Xie et al.   Cell Reports

A phase I pharmacodynamic and pharmacokinetic study of a Ras inhibitor, PRLX 93936, in patients with advanced solid tumors.

(2017) R. K. Ramanathan et al.   JOURNAL OF CLINICAL ONCOLOGY

Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies

(2016) Giuseppa Pistritto et al.   Aging-US

NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer

(2016) Iok In Christine Chio et al.   CELL

Ferroptosis: process and function

(2016) Y Xie et al.   CELL DEATH AND DIFFERENTIATION

Corrigendum to ‘L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells’

(2016) S.A. Jung et al.   FREE RADICAL BIOLOGY AND MEDICINE

Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis

(2016) Kenichi Shimada et al.   Nature Chemical Biology

Activation ofSAT1engages polyamine metabolism with p53-mediated ferroptotic responses

(2016) Yang Ou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting

(2016) A. J. Aguirre et al.   Cancer Discovery

Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic

(2016) Kerri A. Ohman et al.   Oncotarget

Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer

(2016) Oscar Aguilera et al.   Oncotarget

Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors

(2015) Christopher J. Lord et al.   Annual Review of Medicine

Incorporation of metabolically stable ketones into a small molecule probe to increase potency and water solubility

(2015) Marie-Helene Larraufie et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Clinicopathological significance of nuclear factor (erythroid-2)-related factor 2 (Nrf2) expression in gastric cancer

(2015) Yota Kawasaki et al.   BMC CANCER

Dynamic roles of p53-mediated metabolic activities in ROS-induced stress responses

(2015) Le Jiang et al.   CELL CYCLE

Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity—implications for therapeutic targeting of Nrf2

(2015) Adedamola Olayanju et al.   FREE RADICAL BIOLOGY AND MEDICINE

A Synthetic Lethal Interaction between Glutathione Synthesis and Mitochondrial Reactive Oxygen Species Provides a Tumor-Specific Vulnerability Dependent on STAT3

(2015) Daniel J. Garama et al.   MOLECULAR AND CELLULAR BIOLOGY

Glutaminolysis and Transferrin Regulate Ferroptosis

(2015) Minghui Gao et al.   MOLECULAR CELL

Comprehensive genomic characterization of head and neck squamous cell carcinomas

(2015)   NATURE

Ferroptosis as a p53-mediated activity during tumour suppression

(2015) Le Jiang et al.   NATURE

Gene essentiality and synthetic lethality in haploid human cells

(2015) V. A. Blomen et al.   SCIENCE

Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH

(2015) J. Yun et al.   SCIENCE

Nrf2 Overexpression Predicts Prognosis and 5-FU Resistance in Gastric Cancer

(2014) Xiu-Feng Hu et al.   Asian Pacific Journal of Cancer Prevention

Regulation of Ferroptotic Cancer Cell Death by GPX4

(2014) Wan Seok Yang et al.   CELL

Discovery and saturation analysis of cancer genes across 21 tumour types

(2014) Michael S. Lawrence et al.   NATURE

Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice

(2014) Jose Pedro Friedmann Angeli et al.   NATURE CELL BIOLOGY

Applying Synthetic Lethality for the Selective Targeting of Cancer

(2014) Donal P. McLornan et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas

(2013) A. J. Wagner et al.   CLINICAL CANCER RESEARCH

Hereditary breast and ovarian cancer susceptibility genes (Review)

(2013) HIROSHI KOBAYASHI et al.   ONCOLOGY REPORTS

Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis

(2013) Martin Stangel et al.   Expert Review of Clinical Pharmacology

Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death

(2012) Scott J. Dixon et al.   CELL

A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors

(2012) K. Jhaveri et al.   CLINICAL CANCER RESEARCH

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

(2012) Sören Lehmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers

(2011) Komal Jhaveri et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Development of small-molecule probes that selectively kill cells induced to express mutant RAS

(2011) Michel Weïwer et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

(2011) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

(2011) Thomas Helleday   Molecular Oncology

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis

(2011) Gina M. DeNicola et al.   NATURE

Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma

(2010) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Synthetic lethality: General principles, utility and detection using genetic screens in human cells

(2010) Sebastian M.B. Nijman   FEBS LETTERS

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

(2010) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

(2010) J E Lancet et al.   LEUKEMIA

ARID1AMutations in Endometriosis-Associated Ovarian Carcinomas

(2010) Kimberly C. Wiegand et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function

(2010) W. Hu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Blinded by the Light: The Growing Complexity of p53

(2009) Karen H. Vousden et al.   CELL

Synthetic Lethal Screening Identifies Compounds Activating Iron-Dependent, Nonapoptotic Cell Death in Oncogenic-RAS-Harboring Cancer Cells

(2008) Wan Seok Yang et al.   CHEMISTRY & BIOLOGY

Patients With Acute Myeloid Leukemia andRASMutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study

(2008) Andreas Neubauer et al.   JOURNAL OF CLINICAL ONCOLOGY